Sunday , October 22 2017
Home / Letter From The Editor / Letter from the Editor, SGLT-2 Inhibitors, Special Edition #2

Letter from the Editor, SGLT-2 Inhibitors, Special Edition #2

Last month, in our first issue of these special edition newsletters we gave you the tools to become an expert on SGLT2-I therapy. In our second edition we want to help you dig deeper into this new class of drugs. To that end we have some great information for you.

The American Association of Clinical Endocrinologists (AACE) meeting in Phoenix brought researchers and clinicians with the latest information on SGLT2-I developments, and we have that for you. In addition we reached out to clinicians in practice all over the country to see how they perceived this new class and whether or not they were prescribing it to their patients.

While we all understand the potential for the SGLT2-I’s, for the majority of us the prescribing will be controlled by insurance coverage. After speaking with Irl B. Hirsch, M.D. Diabetes Treatment and Teaching Chair at the University of Washington School of Medicine, I decided to put together a list of which plans offered coverage and how much it will cost the patient.